55
Participants
Start Date
October 31, 2011
Primary Completion Date
December 31, 2015
Study Completion Date
October 31, 2016
VAL-083 (Dianhydrogalactitol)
VAL-083 given by intravenous infusion with a starting dose of 1.5 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
Florida Cancer Specialists, Sarasota
Sarah Cannon Research Institute, Nashville
Mayo Clinic, Rochester
Sarah Cannon Research Institute, Denver
University of California, San Francisco, Division of Neuro-Oncology, San Francisco
Lead Sponsor
Kintara Therapeutics, Inc.
INDUSTRY